| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4931 | Stat3 -in-11 | Novel STAT3 inhibitor, selectively inhibiting STAT3 phosphorylation and exhibiting potent antitumor activity |
|
| DCC4932 | stat3 Inhibitor 6 | Novel inhibitor of STAT3 signaling pathway |
|
| DCC4933 | Stat3-in-13r | Novel inhibitor of STAT3, targeting SH2 domain |
|
| DCC4934 | Stat3-in-3 | Novel potent and selective inhibitor of STAT3 |
|
| DCC4935 | Stat3-in-a69 | Novel inhibitor targeting the DNA-binding domain of STAT3, suppressing tumor growth, metastasis and STAT3 target gene expression in vivo |
|
| DCC4936 | Stat3-in-b9 | Novel inhibitor of signal transducer and activator of transcription 3 (STAT3), inhibiting the proliferation of tumor cells harboring abnormal activation of STAT3, such as, MDA-MB-468, MDA-MB-231 and DU145 |
|
| DCC4937 | Stat5a-in-27 | Novel cell-permeable selective STAT5a inhibitor prodrug, inhibiting tyrosine phosphorylation of STAT5a with selectivity over STAT5b in cultured human leukemia cells, and representing a valuable tool to define the non-redundant molecular functions of the t |
|
| DCC4938 | Stat5b-in-6a | Highly Potent and Selective Inhibitor of the Transcription Factor STAT5b |
|
| DCC4939 | Stemazole | Novel human stem/progenitor cells proliferation activator, promoting survival and preserving stemness in human embryonic stem cells |
|
| DCC4940 | Sterigmatocystin | Natural inducer of G1 arrest in primary human esophageal epithelial cells but G2 arrest in immortalized cells |
|
| DCC4941 | Stf-038533 | Novel inhibitor of expression from canonical CREB response element-containing promoters |
|
| DCC4942 | Stg -001 | Novel RBP4 antagonist for treatment of Stargardt disease |
|
| DCC4943 | Stictic Acid | Natural anti-feline infectious peritonitis virus (FIPV) agent, specifically targeting the 3CLpro of FIPV and inhibiting its replication |
|
| DCC4944 | Sting Agonist 11 | Novel non-nucleotide STING agonist, demonstrating antitumor activity when dosed intratumorally in a syngeneic mouse model |
|
| DCC4945 | Sting Inhibitor C-171 | Novel covalent antagonist of hsSTING |
|
| DCC4946 | Stk-15 | Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor |
|
| DCC4947 | Stk-22 | Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor |
|
| DCC4948 | Stk295900 | Dual inhibitor of topoisomerase 1 and 2, inducing G(2) arrest in the absence of DNA damage. Inhibitor of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay |
|
| DCC4949 | Stk508411 | Novel inhibitor of the heterogeneous ribonuclear protein A18 (hnRNP A18) |
|
| DCC4950 | Stk630921 | Novel blocker of IL-17A binding to the IL-17A receptor (IL-17RA) |
|
| DCC4951 | Stk683963 | Novel activator of cellular ATG4B activity |
|
| DCC4952 | Stock1n-65837 | Potent natural modulator of human Toll-like receptor 7 (TLR7) |
|
| DCC4953 | Streptolidine | Metablite of the Streptomyces antibiotics streptothricin and streptolin |
|
| DCC4954 | Streptozocin | Antibiotic, being used as an antineoplastic agent and to induce diabetes in experimental animals |
|
| DCC4955 | Sts-e412 | The first nonpeptidyl, selective activator of the tissue-protective EPOR/CD131 receptor |
|
| DCC4956 | Sts-e424 | Novel agonist of the tissue-protective erythropoietin (EPO) receptor, increasing FXN expression and EPOR phosphorylation |
|
| DCC4957 | Stx-2622 | Inhibitor of 17β-hydroxysteroid dehydrogenases (17β-HSDs) |
|
| DCC4958 | Stx2845 | Novel Nonsteroidal Inhibitor of Carbonic Anhydrase IX |
|
| DCC4959 | Su0383 | Novel dual Inhibitor of repair enzymes 8-oxoguanine DNA glycosylase (OGG1) and human MutT Homolog 1 (NUDT1 or MTH1), increasing sensitivity of tumor cells to oxidative stress |
|
| DCC4960 | Su11272 | Novel potent c-MET inhibitor |
|
